|
|
Prepublished online as a Blood First Edition Paper on May 29, 2003; DOI 10.1182/blood-2003-02-0365.
 Previous Article | Table of Contents | Next Article 
Blood, 1 October 2003, Vol. 102, No. 7, pp. 2555-2561
NEOPLASIA
A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy
Brian R. Stoll,
Cristiano Migliorini,
Ananth Kadambi,
Lance L. Munn, and
Rakesh K. Jain
From the Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA.
The traditional view of angiogenesis emphasizes proliferation and migration of vessel wall-associated endothelial cells. However, circulating endothelial progenitor cells have recently been shown to contribute to tumor angiogenesis. Here we quantify the relative contributions of endothelial and endothelial progenitor cells to angiogenesis using a mathematical model. The model predicts that during the early stages of tumor growth, endothelial progenitors have a significant impact on tumor growth and angiogenesis, mediated primarily by their localization in the tumor, not by their proliferation. The model also shows that, as the tumor grows, endothelial progenitors adhere preferentially near the tumor periphery, coincident with the location of highest vascular density, supporting their potential utility as vectors for targeted delivery of therapeutics. Model simulations of various antiangiogenic strategies show that those therapies that effectively target both endothelial and endothelial progenitor cells, either by restoring the balance between angiogenic stimulators and inhibitors or by targeting both types of cells directly, are most effective at delaying tumor growth. The combination of continuous low-dose chemotherapy and antiangiogenic therapy is predicted to have the most significant effect on therapeutic outcome. The model offers new insight into tumor angiogenesis with implications for the rational design of antiangiogenic therapy. (Blood. 2003;102:2555-2561)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Purhonen, J. Palm, D. Rossi, N. Kaskenpaa, I. Rajantie, S. Yla-Herttuala, K. Alitalo, I. L. Weissman, and P. Salven
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth
PNAS,
May 6, 2008;
105(18):
6620 - 6625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. Schatteman, M. Dunnwald, and C. Jiao
Biology of bone marrow-derived endothelial cell precursors
Am J Physiol Heart Circ Physiol,
January 1, 2007;
292(1):
H1 - H18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ribba, P. Tracqui, J.-L. Boix, J.-P. Boissel, and S. R. Thomas
QxDB: a generic database to support mathematical modelling in biology
Phil Trans R Soc A,
June 15, 2006;
364(1843):
1517 - 1532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Young, M. Whissell, J. C.S. Noble, P. O. Cano, P. G. Lopez, and C. J. Germond
Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors.
Clin. Cancer Res.,
May 15, 2006;
12(10):
3092 - 3098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Iwakura, S. Shastry, C. Luedemann, H. Hamada, A. Kawamoto, R. Kishore, Y. Zhu, G. Qin, M. Silver, T. Thorne, et al.
Estradiol Enhances Recovery After Myocardial Infarction by Augmenting Incorporation of Bone Marrow-Derived Endothelial Progenitor Cells Into Sites of Ischemia-Induced Neovascularization via Endothelial Nitric Oxide Synthase-Mediated Activation of Matrix Metalloproteinase-9
Circulation,
March 28, 2006;
113(12):
1605 - 1614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Rossig, C. Urbich, T. Bruhl, E. Dernbach, C. Heeschen, E. Chavakis, K.-i. Sasaki, D. Aicher, F. Diehl, F. Seeger, et al.
Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells
J. Exp. Med.,
June 6, 2005;
201(11):
1825 - 1835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jodele, C. F. Chantrain, L. Blavier, C. Lutzko, G. M. Crooks, H. Shimada, L. M. Coussens, and Y. A. DeClerck
The Contribution of Bone Marrow-Derived Cells to the Tumor Vasculature in Neuroblastoma Is Matrix Metalloproteinase-9 Dependent
Cancer Res.,
April 15, 2005;
65(8):
3200 - 3208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. d. Buijs, M. Musters, T. Verrips, J. A. Post, B. Braam, and N. van Riel
Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening
Am J Physiol Heart Circ Physiol,
December 1, 2004;
287(6):
H2651 - H2658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Wang, J. Teruya-Feldstein, Y. Wu, Z. Zhu, D. J. Hicklin, and M. A. S. Moore
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo
Blood,
November 1, 2004;
104(9):
2893 - 2902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Biancone, V. Cantaluppi, D. Duo, M. C. Deregibus, C. Torre, and G. Camussi
Role of L-Selectin in the Vascular Homing of Peripheral Blood-Derived Endothelial Progenitor Cells
J. Immunol.,
October 15, 2004;
173(8):
5268 - 5274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Clin. Cancer Res.,
June 1, 2004;
10(11):
3885 - 3896.
[Full Text]
[PDF]
|
|
|
|
|
